This article is more than 5 years old. Information may no longer be current.
RegeneRx compliance plan accepted by NYSE Amex
BETHESDA, Md. — The NYSE Amex has notified RegeneRx that it will continue listing the company's common stock on the condition that the company comply with all applicable criteria for continued listing on or before Oct. 25, 2010, RegeneRx announced in a press release.
This follows the April disclosure that RegeneRx had fallen short of several of the exchange's continued listing standards, including ownership of less than $6 million in stockholders' equity, losses from continuing operations and net losses accrued during the last 5 fiscal years.
Accordingly, RegeneRx submitted a plan of compliance on May 26.
During the extension period, RegeneRx will be subject to periodic review by the exchange staff to determine whether the company is making progress consistent with its compliance plan. Any failure to make such progress or to regain compliance by Oct. 25,
2010, could result in the commencement of delisting proceedings.
During the extension period, RegeneRx common stock will continue to trade under the symbol "RGN"; however, this symbol is subject to the indicator extension ".BC" to denote noncompliance with the exchange's listing standards.